

Hepatocellular Carcinoma Screening in Patients With Compensated Hepatitis C Virus (HCV)-Related Cirrhosis Aware of Their HCV Status Improves Survival: A Modeling Approach

Abbas Mourad,^{1,2} Sylvie Deuffic-Burban,^{1,2} Nathalie Ganne-Carrié,³ Thibaud Renaut-Vantrois,⁴ Isabelle Rosa,⁵ Anne-Marie Bouvier,⁶ Guy Launoy,⁷ Stéphane Cattan,⁴ Alexandre Louvet,^{1,4} Sébastien Dharancy,^{1,4} Jean-Claude Trinchet,³ Yazdan Yazdanpanah,^{2,8} and Philippe Mathurin^{1,4}

Because of the ongoing debate on the benefit of ultrasound (US) screening for hepatocellular carcinoma (HCC), we assessed the impact of screening on hepatitis C virus (HCV)-related compensated cirrhosis patients aware of their HCV status. A Markov model simulated progression from HCC diagnosis to death in 700 patients with HCV-related compensated cirrhosis aware of their HCV status to estimate life expectancy (LE) and cumulative death at 5 years. Five scenarios were compared: S1, no screening; S2, screening by currently existing practices (57% access and effectiveness leading to the diagnosis of 42% at Barcelona Clinic Liver Cancer stage [BCLC-0/A]); S3, S2 with increased access (97%); S4, S2 with an efficacy of screening close to that achieved in a randomized controlled trial leading to the diagnosis of 87% of patients at stage BCLC-0/A; S5, S3+S4. The analysis was corrected for lead-time bias. Currently existing practices of HCC screening increased LE by 11 months and reduced HCC mortality at 5 years by 6% compared to no screening ($P=0.0013$). Compared to current screening practices, we found that: 1) increasing the rate of access to screening would increase LE by 7 months and reduce HCC mortality at 5 years by 5% ($P=0.045$); 2) optimal screening would increase LE by 14 months and reduce HCC mortality at 5 years by 9% ($P=0.0002$); 3) the combination of an increased rate of access and optimal effectiveness of HCC screening would increase LE by 31 months and decrease HCC mortality at 5 years by 20% ($P<0.0001$). **Conclusion:** The present study shows that US screening for HCC in patients with compensated HCV-related cirrhosis aware of their HCV status improves survival and emphasizes the crucial role of screening effectiveness. (HEPATOLOGY 2014;59:1471-1481)

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and represents 7% of all cancer-related deaths.¹ HCC mainly develops in patients with cirrhosis. Patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) have a yearly risk of HCC of ~2%-

5%.^{2,3} Prognosis is very poor due to late diagnosis, which often prevents curative treatment.⁴

Recent European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) guidelines^{4,5} have recommended the Barcelona Clinic Liver Cancer (BCLC)

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LT, liver transplantation; LE, life expectancy; RR, relative risk; RCT, randomized controlled trial; US, ultrasonographic screening.

From the ¹Inserm U995, Université Lille Nord de France, Lille, France; ²IAME, UMR 1137, Inserm, Paris, France, Univ. Paris Nord Sorbonne Paris Cité, Paris, France; ³Service d'Hépatogastroentérologie, Hôpital Jean Verdier, Bondy, France; ⁴Service Maladies de l'Appareil digestif et de la Nutrition, Hôpital Claude Huriez, Lille, France; ⁵ANGH CHANGH Study Group, Centre Hospitalier Intercommunal, Créteil, France; ⁶Inserm U866, Registre des Cancers digestifs, Dijon, Burgundy, France; ⁷Inserm-UCB U1086, Caen, France; ⁸Service des Maladies infectieuses et tropicales, Hôpital Bichat Claude Bernard, Paris, France.

Received June 9, 2013; accepted November 18, 2013.

Supported by a grant (INCa_1496) from the French National Cancer Institute (INCa), the Cancer Research Association (ARC) and the French National AIDS and Viral Hepatitis Research Agency (ANRS) teamed up to launch an Integrated Research Action Programme on hepatocellular carcinoma (HCC PAIR).

classification staging system for the management of HCC.⁶ A therapeutic algorithm was developed based on the BCLC classification with four stages (0/A, B, C, and D). Curative treatment (surgical resection, liver transplantation (LT), and radiofrequency ablation) is used for patients with early-stage HCC (BCLC-0/A). These curative treatments are the only chance of survival, with an overall 3-year survival rate of ~80%.^{4,7} Patients with intermediate stage disease (BCLC-B) can benefit from transarterial chemoembolization, with a 3-year survival rate of ~30%.⁸ Sorafenib is the only therapeutic option for patients with advanced HCC (BCLC-C).⁹

Screening of patients with cirrhosis includes tests or examinations to detect early-stage cancer and increase the chance of optimal therapeutic options. Screening has been shown to effectively diagnose early-stage HCC in randomized controlled trials (RCTs),^{10,11} controlled, and uncontrolled studies.¹²⁻¹⁵ The benefit of ultrasound (US) in the detection of early-stage HCC has also been confirmed in RCTs.^{16,17} Screening is considered to be validated when there is strong evidence that it improves survival. Although international guidelines recommend US screening of patients with cirrhosis every 6 months by experienced personnel,^{4,5} experts continue to seek conclusive evidence that HCC screening improves survival.^{10,11,18-20} The most effective way to evaluate the impact of HCC screening on survival would be to perform an RCT assessing the influence of screening in patients with compensated cirrhosis who are candidates for curative treatment. However, randomization is considered unethical by patients and clinicians, who refuse to prevent patients from receiving the benefits of screening, i.e., early-stage diagnosis.²¹ Controlled or uncontrolled cohort studies may be an alternative approach. However, besides their well-known limitations, non-RCTs also have a lead-time bias (an apparent improvement in survival due to early diagnosis), although certain studies have taken this bias into account.^{19,22-24} A recent cohort study questioning the impact of HCC screening on survival in patients with alcoholic cirrhosis has

added to this controversy.²⁵ However, that study had a major bias because it included patients with decompensated cirrhosis in whom curative therapies are usually not indicated.

The use of a model-based approach is complementary to controlled and uncontrolled studies because it has different goals and uses an analytic methodology that accounts for events over time and across populations. Because of the methodological issues of HCC screening, modeling can be interesting to determine the impact of HCC screening on survival and to test different screening protocols with corresponding therapeutic options according to tumor stage. It can also take into account the lead-time bias. To develop a model, data on the progression of HCC, on the impact of therapeutic options on survival, on the availability of liver grafts for HCC patients, and on the probability of entering into a screening program and being treated according to tumor stage must all be robust.^{16,26} Because these data are often available for HCV patients and because most patients with decompensated cirrhosis are not candidates for treatment, we focused on an HCV-related HCC population with compensated cirrhosis to optimize the accuracy of the model.

The goal of this study was to assess the influence of routine US screening for HCC in patients with compensated HCV-related cirrhosis aware of their HCV status upon survival using a model-based analysis by comparing current HCC screening practices to: 1) no screening; and 2) different scenarios that increase the rate of access to HCC screening and improve the effectiveness of screening.

Materials and Methods

Analytic Overview

A Markov model of the progression of HCC in compensated HCV-related cirrhosis was developed using TreeAge Pro suite 2009 (TreeAge Software). Life expectancy (LE) and the risk of HCV-related HCC deaths from the date of diagnosis were calculated

Address reprint requests to: Philippe Mathurin, Service des Maladies de l'Appareil Digestif et de la Nutrition, Pôle Médico Chirurgical, Hôpital Huriez, CHRU Lille, 1 place de Verdun, 59037 Lille Cedex, France. E-mail: philippe.mathurin@chru-lille.fr; fax: +33 (0)3 20 44 55 64, or Sylvie Deuffic-Burban, ATIP-AVE-NIR, Inserm U995, Parc Eurasanté, 152 rue du Docteur Yersin, 59120 Loos, France. E-mail: sylvie.burban@inserm.fr

Copyright © 2014 by the American Association for the Study of Liver Diseases.

View this article online at wileyonlinelibrary.com.

DOI 10.1002/hep.26944

Potential conflict of interest: Dr. Yazdanpanah consults for Abbott, Bristol-Myers Squibb, Gilead, Tibotec, ViiV Healthcare, and MSD.

Additional Supporting Information may be found in the online version of this article.




Fig. 1. Model of HCV-related HCC progression. Patients staged by the BCLC classification at diagnosis and according to whether or not they were in a screening program for HCC. Patients were given therapeutic options according to BCLC stage. For each cycle, patients (treated or not) either remained alive and received the next cycle or died from HCV-related HCC.

according to different rates of access to HCC screening and to the effectiveness of screening in detecting early-stage HCC. All analyses were corrected for lead-time bias.

Model Overview

This model describes the progression from the time of HCC diagnosis to death from HCV-related HCC in patients with mono-infection and compen-

sated cirrhosis (Fig. 1). The population was first stratified by age (<70 years old, ≥70 years old), a factor which affects therapeutic options, and then by HCV status (known or not), since awareness of HCV status influences HCC screening. HCV-related HCC patients were then staged according to the BCLC classification (0/A, B, C, D) and preestablished prognostic variables.⁶ Patients were treated according to BCLC stage: BCLC-0/A patients received surgical

Table 1. Distribution by BCLC Stage

	Baseline (range)		Sources
Distribution of HCV-related HCC in BCLC stages			
Patients who did not undergo HCC screening			(26)
BCLC-0/A		18%	
BCLC-B		13%	
BCLC-C		60%	
BCLC-D		9%	
Patients who underwent current HCC screening			(26)
BCLC-0/A		42%	
BCLC-B		25%	
BCLC-C		32%	
BCLC-D		1%	
Patients who underwent optimal HCC screening			(16)
BCLC-0/A		87%	
BCLC-B		6%	
BCLC-C		7%	
BCLC-D		0%	
Therapeutic options for HCC patients	< 70 years	≥ 70 years	(26)
BCLC-0/A			
Resection	12.0%	12.0%	
Candidates for liver transplantation	39.0%	0.0%	
Radiofrequency ablation	44.0%	44.0%	
Chemo-embolization	3.0%	27.0%	
Sorafenib*	0.0%	0.0%	
Supportive care	2.0%	17.0%	
BCLC-B			
Candidates for liver transplantation	38.0%	0.0%	
Chemo-embolization	22.0%	40.0%	
Sorafenib*	20.0%	30.0%	
Supportive care	20.0%	30.0%	
BCLC -C			
Sorafenib*	34.0%	34.0%	
Supportive care	66.0%	66.0%	
BCLC-D			
Supportive care	100%	100%	
Drop out from list of transplantation			(45)
Milan ⁺		6%	
Milan-		20%	
Treatments after drop out from list of transplantation			
Chemo-embolization	25% (20%-30%)		
Sorafenib	50% (40%-60%)		
Supportive care	25% (20%-30%)		

Patients who did not undergo HCC screening (26), who underwent currently existing practices of HCC screening (26), and who underwent optimal effectiveness of HCC screening (16), and distribution of therapeutic options for HCC patients according to BCLC stage.

*Date of initial sorafenib marketing authorization was July 19, 2006 (46).

resection, LT, radiofrequency ablation, and/or transarterial chemoembolization; BCLC-B received LT, transarterial chemoembolization, and/or sorafenib; BCLC-C patients received sorafenib; and BCLC-D patients received supportive care. Liver transplantation was limited by the number of available grafts allotted to patients with HCV-related HCC in compensated cirrhosis. Some patients received supportive care because of contraindications that were or were not related to liver disease. Finally, the risk of HCV-related mortality depended on treatment and tumor stage.

Input Data

Rate of HCC Screening. Our working hypothesis was that HCC screening is related to the awareness of HCV status. Patients had to be aware of their HCV status and have been diagnosed with compensated cirrhosis to be screened for HCC. We first estimated the existing rate of screening for HCC in HCV-related cirrhosis based on data from the literature.²⁷ In that cohort,²⁷ 28.5% of all patients with HCV-related cirrhosis (aware or not of HCV status) had access to HCC screening. Considering that 49.7% of the HCV patients were aware of their HCV status,²⁸ we assumed that 57% of these patients had access to HCC screening (i.e., $(49.7\% \times \text{access-rate})_{\text{HCV-known}} + (50.3\% \times 0\%)_{\text{HCV-unknown}} = 28.5\% = > \text{access-rate}_{\text{HCV-known}} = 57\%$). The rates of currently existing practices of HCC screening correspond to the percentage of patients with cirrhosis who have access to HCC screening.

Effectiveness and Efficacy of US Screening According to BCLC Stages (Table 1). Patients with compensated HCV-related HCC were classified by BCLC stage and depending on whether they were entered into an HCC screening program. Distribution of patients by BCLC stage without HCC screening and according to currently existing practices of HCC screening was based on data from the CHANGH cohort in HCV patients²⁶; CHANGH is a prospective French cohort study performed from May 2008 to October 2009 in 98 French community hospitals and five Tertiary Care Hepatology Units.²⁶ The CHANGH cohort described the epidemiological characteristics, management, and survival of HCC in real-life practice in France. All inpatients and outpatients with newly diagnosed HCC were prospectively and consecutively included. The cohort included 1,027 patients. In all, 178 cases of HCC were related to HCV infection (17%) and compensated cirrhosis (110 Child A, 42 Child B, and 26 Child C) was present in 62%. Forty-two percent of patients who were in an HCC screening program were BCLC-0/A, 25% BCLC-B, 32% BCLC-C, and 1% BCLC-D at diagnosis. In contrast, 18% of patients who had not been screened for HCC were BCLC-0/A, 13% BCLC-B, 60% BCLC-C, and 9% BCLC-D at diagnosis.

We defined the effectiveness of screening (performance under real-world conditions) as its capacity to detect early HCC (BCLC-0/A). Thus, according to the CHANGH cohort the effectiveness of current US screening practices was the diagnosis of 42% of HCC in compensated HCV-related cirrhosis at stage BCLC-0/A.²⁶ The efficacy of US screening (performance under best-case scenario, e.g., RCT) in the randomized CHC-2000 trial was the diagnosis of 87% of HCC in compensated HCV-related cirrhosis at BCLC-0/A.¹⁶

Therapeutic Options and Survival. The possible therapeutic options according to BCLC stage and patient age were obtained from the CHANGH cohort (Table 1). Sixty-three percent of patients <70 years old who were candidates for LT were within to the Milan criteria (BCLC-0/A), while 37% of patients were outside the criteria (BCLC-B). These data were similar to those from the French National Agency for Organ Sharing and Transplantation (Agence de la Biomédecine) (62% and 38%, respectively).²⁹ Our model included the hypothesis that some patients in the BCLC-0/A group received chemoembolization or supportive care due to deterioration of liver function, tumor progression, or other complications. Moreover, some candidates for LT were removed from the list because of tumor progression and death related to liver deterioration or other factors, and consequently received palliative treatment. LT is not considered a therapeutic option in patients over 70³⁰ and the probability of these patients receiving therapeutic management is reduced due to a higher prevalence of comorbidity than in younger patients.²⁶ Overall, 36% of patients under 70 were not considered for therapeutic management, compared to 45% of patients over 70.

Survival rates after treatment for HCC in compensated HCV-related cirrhosis were estimated taking into account tumor progression and the complications of cirrhosis and based on publications in the literature (Supporting Table 2).

Procedure

Validity of the Model. To determine the validity of our model, we simulated the progression from diagnosis until death of all compensated HCV-related HCC patients in France (both those aware and not aware of their HCV status) who were still alive in 2001, along with new cases from 2001 to 2010³¹ (Supporting Table 1 and Supporting Material for more details).

Application. To assess the impact of HCC screening, we simulated a population of 700 HCV-related HCC patients in France corresponding to newly diagnosed patients with HCC and compensated cirrhosis in 2013 who were aware of their HCV status (41% <70 years old, 59% ≥70 years old).³¹ We estimated LE and cumulative death at 5 years from the date of diagnosis of HCC according to five scenarios: scenario 1, no access to HCC screening; scenario 2, currently existing practices of HCC screening,²⁶ i.e., access to screening in 57% and effectiveness of screening with 42% of patients diagnosed at BCLC-0/A; scenario 3, scenario 2 with an increase in access to screening to

97%; scenario 4, scenario 2 with an efficacy of screening corresponding to optimal HCC screening as observed in the CHC-2000 randomized trial (87% of patients diagnosed at BCLC-0/A)¹⁶; scenario 5, scenario 3 + scenario 4.

Finally, we estimated the gain in LE and relative risk (RR) of death 5 years after the diagnosis of HCC for scenario 2 compared to scenario 1, and for scenarios 3, 4, and 5 compared to scenario 2.

Lead-Time Bias

Lead-time bias corresponds to improved survival due to early detection of the disease, but with no effect on disease outcome³² (Fig. 2). Survival in scenarios 2 to 5 was corrected for lead-time (see Detailed Methodological Information in the Supporting Materials).

Statistical Analysis

The chi-square test was used to compare risk of death at 5 years in the different scenarios. A 2-tailed *P*-value <0.05 was considered statistically significant. Statistical analysis was performed with NCSS 2007 software.

Sensitivity Analysis

Sensitivity analysis was performed in two steps to evaluate the impact of data uncertainty and to determine the robustness of our overall conclusions. The first step evaluated the impact of HCC screening (scenario 2 versus scenario 1) on LE and the risk of death at 5 years by varying the model variables (see more details in Supporting Materials): effectiveness of HCC screening, rate of access to HCC screening, rate of access to treatment, survival rates after the most efficient treatment options (i.e., resection, transplantation, radiofrequency ablation, and chemoembolization) and tumor volume doubling time. Moreover, we simultaneously varied the two variables, effectiveness of screening and rate of access to screening, to determine when HCC screening still improved 5-year mortality compared to scenario 1. The second step evaluated the impact of alternative scenarios (scenarios 3, 4, and 5 versus scenario 2) on LE and risk of death at 5 years varying the most important variables (see more details in Supporting Materials).

Results

Validity of the Model. We validated the predictive performance of the model for yearly HCV-related HCC deaths and yearly LT for compensated HCV-related HCC. First, the relative mean difference




Fig. 2. Illustration of lead-time bias based on three screening situations: case A, no screening; case B, screening with no impact on survival; and case C, screening with an impact on survival. We assumed that all HCC developed at the same time, but cases B and C were diagnosed earlier than case A. Without screening, case A was diagnosed when clinical signs or symptoms had developed. Case B was diagnosed by screening before symptoms developed, but both patients (A and B) died at the same time. The longer survival time for patient B simply reflected a longer time from cancer detection to its clinical diagnosis. Patient C was diagnosed by screening at the same time as patient B but died later than patients A and B. Although there existed a true benefit in terms of survival, perceived survival was still higher than true survival.

between estimated and observed HCV-related HCC deaths from 2002 to 2010 was 1% (range, 0%-5%) (Supporting Fig. 1). Second, the relative mean difference between estimated and observed numbers of LT for compensated HCV-related HCC was 6% (range, 2%-10%) (Supporting Fig. 2).

Life Expectancy. Current HCC screening practices (scenario 2) were associated with an 11-month increase in LE compared to the absence of screening (scenario 1), (Fig. 3A). Compared to currently existing practices of HCC screening practices (scenario 2): 1) increasing the rate of access to HCC screening from 57% to




Fig. 3. Life expectancy according to five HCC screening scenarios. Months of life saved appear in light gray areas, after comparison of (A) scenario 2 with scenario 1 and (B) scenarios 3, 4, and 5 with scenario 2.




Fig. 4. Cumulative mortality of HCV-related HCC at 5 years corrected for lead-time according to: (A) scenario 2 versus scenario 1; (B) scenarios 3, 4, and 5 versus scenario 2

97% (scenario 3) increased the LE by 7 months; 2) increasing the effectiveness of HCC screening from 42% to 87% (scenario 4) increased the LE by 14 months; 3) improving the rate of access to HCC screening as well as its effectiveness (scenario 5) increased the LE by 31 months (Fig. 3B).

HCV-Related HCC Mortality at 5 Years. The 5-year risk of HCV-related HCC death was 90.8%, 85.3%, 81.4%, 77.5%, and 68.4% in scenarios 1, 2, 3, 4, and 5, respectively (Fig. 4). Thus, there was a 6% reduction in HCV-related HCC mortality with current HCC screening practices (scenario 2), compared to without HCC screening (scenario 1): RR = 0.95 (95% confidence interval [CI]: 0.91-0.98; $P = 0.0013$, Fig. 4A). Once again, increasing the rate of access to HCC screening from 57% to 97% (scenario 3 versus scenario 2) reduced mortality by 5%: RR = 0.95 (95% CI: 0.91-1.00; $P = 0.045$, Fig. 4B). In contrast the efficacy of HCC screening, such as in clinical trial CHC 2000, significantly improved HCV-related HCC mortality (scenario 4 versus scenario 2): RR = 0.91 (95% CI: 0.86-0.96; $P = 0.0002$, Fig. 4B). Finally, the influence of increasing access to screening and the effectiveness of HCC screening (scenario 5 versus scenario 2) was even greater: RR = 0.80 (95% CI: 0.75-0.85; $P < 0.0001$, Fig. 4B).

Sensitivity Analysis. Figure 5 shows the most influential variables in the model. LE and risk of death at 5 years were most sensitive to the effectiveness of HCC screening and the rate of access to HCC screening. When comparing scenario 2 to scenario 1: 1) LE increased by 7 to 25 months when varying the effectiveness of screening and by 4 to 14 months when

varying the rate of access to screening (11 months in baseline analysis); 2) HCV-related HCC mortality was reduced by 4% to 15% when varying the effectiveness of screening (6% in baseline analysis) and by 2% to 10% when varying the rate of access to screening (6% in baseline analysis). Moreover, a 20% rate of access to screening did not significantly impact LE (+4 months) and HCV-related HCC mortality at 5 years (−2%) ($P = 0.18$) (Fig. 6). Therefore, for screening to be beneficial, the minimum rate of access to screening should be 34% with a 42% effectiveness and the minimum effectiveness of screening should be 31% with a 57% rate of access to screening. This interaction between the effectiveness and the rate of access to screening is illustrated in Fig. 7. It shows the minimum rate of access and effectiveness of HCC screening necessary for these variables. The results of additional sensitivity analyses are shown in the Supporting Material (Supporting Figs. 3-5).

Discussion

American and European guidelines on screening for HCC are a subject of debate^{33,34} since some investigators consider that data from RCTs on the impact on survival are not reliable. However, it is ethically impossible to perform RCTs to assess the impact of screening on survival with a design that includes an arm without screening.²¹ The present study uses a model that provides more facts and less speculation on the survival benefit of HCC screening at diagnosis. All of the different scenarios showed that HCC screening led to a substantial increase in LE and decreased the risk




Fig. 5. Sensitivity analysis. This tornado diagram shows the effect of different degrees of effectiveness of HCC screening, rates of access to screening, rates of access to treatment, survival rates after resection, survival rates after transplantation, survival rates after radiofrequency ablation, and survival rates after chemoembolization, as well as tumor volume doubling time, on: (A) variation of life expectancy (scenario 2 versus 1), (B) relative risk of death at 5 years (scenario 2 versus 1). The values in curly brackets are the plausible range tested in sensitivity analysis, the solid line indicates results (variation of life expectancy and relative risk of death at 5 years) with the baseline parameters, the bars show the variability on results caused by changes in the indicated variable, all other variables held constant.




Fig. 6. Sensitivity analysis corresponding to a decrease in access rate to HCC screening from 57% to 20%.³⁹ Life expectancy corrected for lead-time according to five HCC screening scenarios: (A) light gray area is the number of life months saved by scenario 2 compared to scenario 1; (B) light gray areas are numbers of life months saved by scenario 3, 4, and 5 compared to scenario 2. Cumulative mortality of HCV-related HCC at 5 years corrected for lead-time according to: (C) scenario 2 versus scenario 1; (D) scenarios 3, 4, and 5 versus scenario 2.

of HCV-related HCC death in patients aware of their HCV status. Scenarios that include improving the effectiveness of HCC screening were the most efficient, with the greatest increase in LE of 31 months for the scenario combining the efficacy of HCC screening

with an increase in access to screening. Analysis of the different variations of rates of access to screening and effectiveness of screening show the impact of their interaction on mortality from HCC at 5 years.

In France, as in other countries, screening for HCC is not standard in real clinical practice. It should be noted that screening rates vary drastically according to the type of center and hospital, with higher rates of screening for HCC in tertiary-care centers³⁵ or primary care practices³⁶ than those observed in the national registration database.^{27,37}

Ideally, the design of studies testing the benefits of screening on survival should: 1) only include patients with compensated cirrhosis; indeed, patients with decompensated cirrhosis are often not candidates for treatment; 2) provide appropriate therapeutic options to patients, especially curative treatment for early-stage disease; 3) integrate the limited availability of liver grafts; 4) take into account lead-time bias. Most studies have not fulfilled all of these prerequisites. Our




Fig. 7. Zones corresponding to the benefit of HCC screening on survival (dark gray) or not (light gray) by simultaneously varying screening effectiveness and access to screening. The curve corresponds to the limit of significance between the scenarios with and without screening. For example, at dot X with a 42% effectiveness of screening, the minimum access rate to screening would be 34% for screening to be beneficial; at dot Y with a 57% access to screening, the minimum effectiveness of screening would be 31% to have benefit from screening.

study only evaluated patients with compensated cirrhosis. The proportion of HCV-related HCC patients with compensated cirrhosis in whom curative treatment was indicated increased from 14.4% in those without HCC screening to 25.0% with current HCC screening, to 40.0% with an efficacy of screening corresponding to optimal HCC screening and 58.5% when the rate of access to screening was increased and the effectiveness of screening was improved. We also attributed a limited number of LT based on real-data.³⁸ Finally, we took into account lead-time bias and also performed sensitivity analysis according to tumor growth, thus guaranteeing the reliability of results. However, these results cannot be extrapolated to other etiologies of cirrhosis, since part of the modeling data are lacking for non-HCV-related HCC.

At first glance, increasing the rate of access to screening appears to be an easy way to improve the outcome of patients with HCC. Our baseline assumption of a rate of access to screening of 57% may at first glance appear to be different from the rate of around 20% that has been reported in the general population.^{27,39} However, our study was limited to HCV patients with cirrhosis who were aware of their HCV status while in the global HCV population (aware or not of their virological status), the rate of access to screening is markedly lower because patients who are not aware of their HCV status are, by definition, not in an HCC screening program because their liver disease is undiagnosed. Our results show that a 20% rate of access to screening was not effective. Because this rate may reflect the rate of access in the general population with cirrhosis,^{27,39} these results strongly suggest that public health policies should not only increase the rate of access to screening in patients aware of their liver disease but also the percentage of patients aware of their HCV status.

The influence of HCC screening on survival has been evaluated in two RCTs.^{10,11} The first study was inconclusive because a large proportion of diagnosed patients did not receive appropriate treatment.¹⁰ Although the second trial showed that HCC screening was beneficial, experts have shown^{34,40} that there were methodological flaws and limitations in the study design.¹¹ Other cost-effectiveness studies in patients with hepatitis C and cirrhosis concluded that US screening provided a benefit in survival.⁴¹⁻⁴³ The main objective of that study was to identify the most cost-effective HCC screening method. Conversely, the goal of our study was to evaluate the impact of US screening on survival in real-life scenarios and to test the influence of different strategies to improve current

screening practices. As suggested in a prior study,⁴⁴ our study showed that the effectiveness of HCC screening was the most important variable. Indeed, compared to currently existing practices of HCC screening, the efficacy of HCC screening increased the number of patients diagnosed with early-stage disease (87% versus 42%) and reduced 5-year mortality by 9%. The efficacy of HCC screening described in RCTs^{16,17} may be due to highly experienced operators and centers, standard quality US material, selection of patients, and strict follow-up. Therefore, we strongly recommend that clinicians and policymakers target the effectiveness of US screening to improve survival in HCC patients.

As expected in a modeling approach, the present work had several limitations because of data from multiple sources and assumptions. The impact of these weaknesses seems to be limited since we focused on available and robust data from HCV patients. In addition, our study took into account lead-time bias. Moreover, we performed sensitivity analysis to assess the potential impact of uncertainties. The results of these sensitivity analyses did not modify the main conclusions of our study and confirmed the robustness of baseline assumptions.

In summary, the present study shows that US screening for HCC in compensated HCV-related cirrhosis improves survival, and emphasizes the importance of screening effectiveness. Policy makers and experts should recommend better training for US operators, standard quality US materials, better education of patients in terms of compliance, better quality follow-up, and an improved multidisciplinary network to increase awareness of the benefits to survival of HCC screening in patients and for general practitioners.

References

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003;362:1907-1917.
2. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, European Concerted Action on Viral H. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. *Am J Gastroenterol* 2002;97:2886-2895.
3. Serfaty L, Aumaitre H, Chazouilleres O, Bonnard AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. *HEPATOLOGY* 1998;27:1435-1440.
4. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *HEPATOLOGY* 2011;53:1020-1022.
5. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012;56:908-943.

6. Llovet JM, Bruix C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999;19:329-338.
7. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; 379:1245-1255.
8. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002;359:1734-1739.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; 359:378-390.
10. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. *J Med Screen* 2003;10:204-209.
11. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2004;130: 417-422.
12. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. *HEPATOLOGY* 2006;43: 1303-1310.
13. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. *J Hepatol* 2010;53:291-297.
14. Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. *Hepatol Int* 2009;3:544-550.
15. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. *Cancer Epidemiol Biomarkers Prev* 2012;21:793-799.
16. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. *HEPATOLOGY* 2011;54:1987-1997.
17. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, et al. Hepatocellular carcinoma surveillance at 4- versus 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. *Am J Gastroenterol* 2013;108:416-424.
18. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. *Gut* 2001;48:251-259.
19. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. *Gut* 2011;60:992-997.
20. Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? *Cancer J* 2004;10:317-325.
21. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? *HEPATOLOGY* 2011;54:1998-2004.
22. Tong MJ, Sun HE, Hsien C, Lu DS. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. *Dig Dis Sci* 2010;55:826-835.
23. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegno L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). *Am J Gastroenterol* 2002;97:734-744.
24. Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, Li YW, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. *Liver Int* 2008;28:79-87.
25. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. *Ann Intern Med* 2012;156:841-847, W295.
26. Rosa I, Lesgourgues B, Renard P, Dobrin AS, Becker C, et al. A French multicentric longitudinal descriptive study of hepatocellular carcinoma management, the CHANGH cohort: preliminary results [Abstract]. *J Hepatol* 2010;52:S231-S232.
27. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. *HEPATOLOGY* 2010;52:132-141.
28. Denniston MM, Kleven RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. *HEPATOLOGY* 2012;55:1652-1661.
29. Le rapport médical et scientifique du prélèvement et de la greffe en France [May 28, 2013]. <http://www.agence-biomedecine.fr/annexes/bilan2011/donnees/organes/05-foie/synthese.htm>.
30. Indications de la transplantation hépatique [May 28, 2013]. http://www.has-sante.fr/portail/upload/docs/application/pdf/Trnsplantation_hepatique_2005_long.pdf.
31. Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. *J Hepatol* 2008;49:175-183.
32. Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, et al. Screening in liver disease: report of an AASLD clinical workshop. *HEPATOLOGY* 2004;39:1204-1212.
33. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. *Ann Intern Med* 2012;156:387-389.
34. Sherman M, Bruix J, Porayko M, Tran T, Committee APG. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. *HEPATOLOGY* 2012; 56:793-796.
35. Singal AG, Volk ML, Rakoski MO, Fu S, Su GL, McCurdy H, et al. Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. *J Clin Gastroenterol* 2011;45: 727-732.
36. Patwardhan V, Paul S, Corey KE, Mazhar SM, Thiim M, Richter JM, et al. Hepatocellular carcinoma screening rates in cirrhotic patients differ by specialty practice. *HEPATOLOGY* 2010;52(S1):1249A.
37. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. *Ann Intern Med* 2011;154:85-93.
38. Agence de la biomédecine [May 28, 2013]. <http://www.agence-biomedecine.fr/Toutes-les-activites-chiffrees>.
39. Singal AG, Yopp A, C SS, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. *J Gen Intern Med* 2012;27:861-867.
40. Colombo M. Screening and diagnosis of hepatocellular carcinoma. *Liver Int* 2009;29(Suppl 1):143-147.
41. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2008;6:1418-1424.
42. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. *Am J Gastroenterol* 2003;98:679-690.
43. Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. *Clin Gastroenterol Hepatol* 2005;3: 75-84.
44. Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? *Am J Gastroenterol* 2013;108:425-432.
45. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. *Liver Transpl* 2009;15:859-868.
46. Commission De La Transparence [May 28, 2013]. http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-5225_nexavar.pdf.